1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry
Status PubMed-not-MEDLINE Jazyk angličtina Země Irsko Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
32953969
PubMed Central
PMC7486438
DOI
10.1016/j.ijcha.2020.100605
PII: S2352-9067(20)30303-1
Knihovny.cz E-zdroje
- Klíčová slova
- COMBO stent, Dual therapy stent, Endothelial progenitor cell capture, NCT02183454, PARIS bleeding risk score,
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization. OBJECTIVE: We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score. METHODS: MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score ≤ 3 and intermediate-to-high (IHBR) for score > 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-driven target lesion revascularization (TLR). Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definition. Dual antiplatelet therapy (DAPT) cessation was independently adjudicated. RESULTS: The study included 56% (n = 1270) LBR and 44% (n = 1009) IHBR patients. Incidence of 1-year TLF was higher in IHBR patients (4.1% vs. 2.6%, p = 0.047) driven by cardiac death (1.7% vs. 0.7%, p = 0.029) with similar rates of MI (1.8% vs. 1.1%, p = 0.17), TLR (1.5% vs. 1.6%, p = 0.89) and definite/ probable stent thrombosis (1.2% vs. 0.6%, p = 0.16). Incidence of 1-year major BARC 3 or 5 bleeding was significantly higher in IHBR patients (2.3% vs. 0.9%, p = 0.0094), as was the incidence of DAPT cessation (29.3% vs. 22.8%, p < 0.01), driven by physician-guided discontinuation. CONCLUSIONS: Patients with intermediate-to-high PARIS bleeding risk in the MASCOT registry experienced greater incidence of 1-year TLF, major bleeding and DAPT cessation than LBR patients, without significant differences in stent thrombosis.
Al Dorrah Heart Center Cairo Egypt
Alhyatt Cardiovascular Center and Tanta University Hospital Egypt
Bina Waluya Hospital Jakarta Indonesia
Breda Amphia Breda Netherlands
Conquest Hospital East Sussex UK
Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong
Hospital Álvaro Cunqueiro Vigo Spain
Hospital of Invasive Cardiology IKARDIA Lublin Nałęczów Poland
Hospital Queen Elizabeth 2 Sabah Malaysia
Hospital Universitario Burgos Burgos Spain
Icahn School of Medicine at Mount Sinai Hospital New York United States
Motol University Hospital Prague Czech Republic
Nemocnice na Homolce Kardiologie Prague Czech Republic
Queen Elizabeth Hospital Kowloon Hong Kong
San Raffaele Hospital Milan Italy
Sarawak Heart Centre Sarawak Malaysia
SUSCCH a s Banska Bystrica Slovakia
T Bata Regional Hospital Zlin Zlin Czech Republic
Zobrazit více v PubMed
Levine G.N., Bates E.R., Bittl J.A. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134:e123–155. PubMed
Chandrasekhar J., Martin K., Mehran R. Role of coronary drug-eluting stents in current clinical practice. Clin. Pharm. 2016 doi: 10.1211/CP.2016.20201885. DOI
Bangalore S. The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents. Circulation. 2019;139:334–336. PubMed
Granada J.F., Inami S., Aboodi M.S. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ. Cardiovasc. Interv. 2010;3:257–266. PubMed
Nakazawa G., Granada J.F., Alviar C.L. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv. 2010;3:68–75. PubMed
Saito S., Krucoff M.W., Nakamura S. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur. Heart J. 2018;39:2460–2468. PubMed PMC
Colombo A., Chandrasekhar J., Aquino M. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int. J. Cardiol. 2019;283:67–72. PubMed
Baber U., Mehran R., Giustino G. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J. Am. Coll. Cardiol. 2016;67:2224–2234. PubMed
Cutlip D.E., Windecker S., Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351. PubMed
Thygesen K., Alpert J.S., Jaffe A.S. Third universal definition of myocardial infarction. Eur. Heart J. 2012;33:2551–2567. PubMed
Mehran R., Rao S.V., Bhatt D.L. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–2747. PubMed
Mehran R., Baber U., Steg P.G. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382:1714–1722. PubMed
Sorrentino S., Claessen B., Mehran R., Kandzari D., Morice M.C., Leon M., Gersh B., Ben-Yehuda O., Redfors B., Dressler O., Pocock S., Kappetein A.P., Sabik J., Serruys P., Stone G. Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. J. Am. Coll. Cardiol. 2018;72(13) doi: 10.1016/j.jacc.2018.08.2078. Supplement. DOI
Jensen C.J., Naber C.K., Urban P. Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy. EuroIntervention. 2018;13:1946–1949. PubMed
Chandrasekhar J, Mehran, R., Genereux, P., Dangas, G., Zhang, Y., McAndrew, T., Kirtane, A., Stone, G. Effect of thrombotic risk and bleeding risk by platelet reactivity status on 2-year mortality: A report from the ADAPT DES study. Journal of the American College of Cardiology March 21, 2017, 69 (11 Supplement) 1012; DOI: 10.1016/S0735-1097(17)34401-7.
Sorrentino S., Sartori S., Baber U. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ. Cardiovasc. Interv. 2020;13(4) PubMed
Sorrentino S., Baber U., Claessen B.E. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thromb. Haemost. 2018;118:1997–2005. PubMed
De Luca G., Damen S.A., Camaro C. Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial. EuroIntervention. 2019;15(11):e990–e998. doi: 10.4244/EIJ-D-19-00539. PubMed DOI
Kirtane A.J., Stone G.W. How to minimize stent thrombosis. Circulation. 2011;124:1283–1287. PubMed
Chandrasekhar J., Baber U., Sartori S. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can. J. Cardiol. 2018;34:319–329. PubMed
Vogel B, Claessen, B., Baber, U., Sorrentino, S., Zhao, W., Krucoff, M., Kozuma, K., Ge, J., Seth, A., Makkar, R., Bangalore, S., Bhatt, D., Angiolillo, D., Saito, S., Neumann, FJ., Hermiller, J. and Valgimigli, M. Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. Journal of the American College of Cardiology. Volume 72, Issue 13 Supplement, September 2018. DOI: 10.1016/j.jacc.2018.08.1723.
Watanabe H., Domei T., Morimoto T. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321:2414–2427. PubMed PMC
Mehran R., Baber U., Sharma S.K. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N. Engl. J. Med. 2019;381(21):2032–2042. doi: 10.1056/NEJMoa1908419. PubMed DOI
Jeremias A, Davies JE, Maehara A. Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019;12(20):1991–2001. doi: 10.1016/j.jcin.2019.05.054. PubMed DOI
Chandrasekhar J., Allada C., O'Connor S. Efficacy of non-compliant balloon post-dilation in optimization of contemporary stents: A digital stent enhancement study. Int. J. Cardiol. Heart Vessel. 2014;3:43–48. PubMed PMC
Hibbert B., Simard T., Ramirez F.D. The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J. Cardiovasc. Pharmacol. 2013;62:491–496. PubMed